--- title: "Cellular Senescence: A Translational Perspective" description: "Targeting senescent cells with senolytic drugs shows promise for treating age-related diseases and chronic conditions by removing harmful cells." url: "https://magellanlongevity.com/study/d28416161.md" canonical: "https://magellanlongevity.com/study/d28416161.html" html: "https://magellanlongevity.com/study/d28416161.html" type: "study" study_key: "d28416161" journal: "EBioMedicine" year: 2017 pmid: "28416161" doi: "10.1016/j.ebiom.2017.04.013" citations: 1 updated: 2026-09-02 author: "Gabriel Radu, DO" author_credentials: "Physiatrist (PM&R). NY medical license 275110. NPI 1376861765." publisher: "Magellan Longevity" content_format: "markdown" --- # Cellular Senescence: A Translational Perspective [Home](https://magellanlongevity.com/) › [Research map](https://magellanlongevity.com/longevity-research-map.html) › Cellular Senescence: A Translational Perspective **HTML version:** https://magellanlongevity.com/study/d28416161.html · **In the Magellan app:** https://magellanlongevity.com/#/study/d28416161 ## Citation | Field | Value | | --- | --- | | Journal | EBioMedicine | | Year | 2017 | | PMID | [28416161](https://pubmed.ncbi.nlm.nih.gov/28416161/) | | DOI | [10.1016/j.ebiom.2017.04.013](https://doi.org/10.1016/j.ebiom.2017.04.013) | | Study key | d28416161 | ## Takeaway Targeting senescent cells with senolytic drugs shows promise for treating age-related diseases and chronic conditions by removing harmful cells. ## The question The abstract does not explicitly state a question, but it investigates the role of cellular senescence in aging and chronic diseases and the potential for therapeutic intervention. ## Hypothesis The abstract implies a hypothesis that targeting senescent cells by inhibiting their pro-survival pathways (SCAPs) could alleviate senescence-associated conditions. ## Methods The authors used a hypothesis-driven approach to discover Senescent Cell Anti-apoptotic Pathways (SCAPs) and subsequently identified senolytic agents based on these pathways. These agents were then tested in pre-clinical models. ## Results Senescent cells accumulate with aging and in chronic diseases, contributing to inflammation, metabolic dysregulation, and other pathologies through the SASP. Delaying or reducing senescent cell burden is linked to improved outcomes. The discovery of SCAPs led to the identification of senolytic agents that alleviate multiple senescence-related phenotypes in pre-clinical models. ## Conclusion Cellular senescence plays a significant role in aging and chronic diseases. Senolytic agents, which target SCAPs and induce senescent cell apoptosis, show promise in pre-clinical models for alleviating senescence-related conditions and are being translated into clinical interventions. ## Limitations The abstract does not explicitly state limitations of the study. It mentions that senolytic agents are 'beginning the process of being translated into clinical interventions,' implying that human clinical data is still emerging or not yet available. ## Verbatim from the abstract > we discover pro-survival Senescent Cell Anti-apoptotic Pathways and the first senolytic agents ## Where this study is used on Magellan This paper is one of the citations behind the evidence grade on the pages below. Grades are assigned from the published research and are independent of affiliate commissions. | Compound or device | Evidence grade | Graded pages | | --- | --- | --- | | Fisetin Senolytic Capsules | Emerging evidence | [Fisetin Senolytic Capsules](https://magellanlongevity.com/p/101.md) | ## Reference 1. **Cellular Senescence: A Translational Perspective** EBioMedicine 2017 · [PMID 28416161](https://pubmed.ncbi.nlm.nih.gov/28416161/) · [DOI 10.1016/j.ebiom.2017.04.013](https://doi.org/10.1016/j.ebiom.2017.04.013) > we discover pro-survival Senescent Cell Anti-apoptotic Pathways and the first senolytic agents ## Structured data ```json {"@context":"https://schema.org","@graph":[{"@type":"MedicalWebPage","@id":"https://magellanlongevity.com/study/d28416161.html#page","url":"https://magellanlongevity.com/study/d28416161.html","name":"Cellular Senescence: A Translational Perspective","description":"Targeting senescent cells with senolytic drugs shows promise for treating age-related diseases and chronic conditions by removing harmful cells.","inLanguage":"en","isPartOf":{"@type":"WebSite","name":"Magellan Longevity","url":"https://magellanlongevity.com/"},"author":{"@type":"Person","name":"Gabriel Radu, DO","jobTitle":"Physiatrist (PM&R)","identifier":[{"@type":"PropertyValue","name":"NPI","value":"1376861765"},{"@type":"PropertyValue","name":"NY medical license","value":"275110"}]},"publisher":{"@type":"Organization","name":"Magellan Longevity","url":"https://magellanlongevity.com/"},"encoding":{"@type":"MediaObject","encodingFormat":"text/markdown","contentUrl":"https://magellanlongevity.com/study/d28416161.md"},"dateModified":"2026-09-02"},{"@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://magellanlongevity.com/"},{"@type":"ListItem","position":2,"name":"Research map","item":"https://magellanlongevity.com/longevity-research-map.html"},{"@type":"ListItem","position":3,"name":"Cellular Senescence: A Translational Perspective","item":"https://magellanlongevity.com/study/d28416161.html"}]},{"@type":"ScholarlyArticle","@id":"https://magellanlongevity.com/study/d28416161.html#study","name":"Cellular Senescence: A Translational Perspective","headline":"Cellular Senescence: A Translational Perspective","datePublished":"2017","isPartOf":{"@type":"Periodical","name":"EBioMedicine"},"identifier":"PMID:28416161","url":"https://pubmed.ncbi.nlm.nih.gov/28416161/","sameAs":"https://doi.org/10.1016/j.ebiom.2017.04.013","abstract":"Targeting senescent cells with senolytic drugs shows promise for treating age-related diseases and chronic conditions by removing harmful cells."}]} ``` ## Related on Magellan Longevity - [Fisetin Senolytic Capsules](https://magellanlongevity.com/p/101.md) — product graded on this and related evidence - [Fisetin is a senotherapeutic that extends health and lifespan.](https://magellanlongevity.com/study/s101.md) - [Senolytic drugs: from discovery to translation](https://magellanlongevity.com/study/d32686219.md) - [Longevity research map](https://magellanlongevity.com/longevity-research-map.html) - [Evidence-based longevity supplements](https://magellanlongevity.com/longevity-supplements.md) ## Scope and disclosures Educational information, not medical advice. Nothing here is intended to diagnose, treat, cure, or prevent any disease. Talk to your physician before starting any supplement or device, especially if you are pregnant, nursing, or taking medication. Editorial firewall: evidence grades are assigned from the published research and are independent of any affiliate commission. As an Amazon Associate, Magellan Longevity earns from qualifying purchases. Reviewed for accuracy by a board-certified physician (DO).